Characteristics | dcSSc, n = 264 | lcSSc, n = 487 | p |
---|---|---|---|
Female | 222 (84.1) | 429 (88.1) | 0.143 |
BMI, kg/m2 | 21.0 ± 3.4 | 23.1 ± 16.6 | 0.088 |
Age at diagnosis, yrs | 47.1 ± 13.3 | 49.9 ± 13.2 | 0.006 |
Onset age of RP, yrs | 42.4 ± 14.5 | 45.6 ± 14.6 | 0.008 |
Onset age of scleroderma, yrs | 44 ± 14.3 | 47.2 ± 14.1 | 0.006 |
Observation period, yrs | 7.2 ± 5.8 | 5.9 ± 5.4 | 0.004 |
Residence in urban area | 222 (84.1) | 362 (74.3) | 0.002 |
mRSS | 13.2 ± 7.2 | 4.3 ± 3.6 | < 0.001 |
GERD | 112 (42.4) | 135 (27.7) | < 0.001 |
ILD | 178 (67.4) | 218 (44.8) | < 0.001 |
Cardiovascular involvement | 45 (17) | 39 (8) | < 0.001 |
PAH | 42 (15.9) | 60 (12.3) | 0.129 |
Isolated PAH | 2 (0.8) | 11 (2.3) | 0.155 |
Renal crisis | 13 (4.9) | 6 (1.2) | 0.002 |
Cancer | 14 (5.3) | 32 (6.6) | 0.528 |
Death | 32 (12.1) | 25 (5.1) | 0.001 |
Pulmonary function test | |||
FVC, % predicted | 72.9 ± 20 | 81.8 ± 19 | < 0.001 |
FEV1, % predicted | 77.8 ± 20.1 | 86.5 ± 20.7 | < 0.001 |
FEV1/FVC, % predicted | 108.2 ± 15.0 | 106.5 ± 12.7 | 0.15 |
DLCO, % predicted | 62.1 ± 22.1 | 67.7 ± 21.3 | 0.004 |
Systolic PAP, mmHg | 33.3 ± 17.2 | 32.0 ± 16.3 | 0.418 |
ANA | 253/258 (98.1) | 462/482 (95.9) | 0.137 |
Anti-Scl-70 antibody | 152/246 (61.8) | 150/464 (32.3) | < 0.001 |
ACA | 25/233 (10.7) | 150/453 (33.1) | < 0.001 |
ARA | 33/195 (16.9) | 57/376 (15.2) | 0.583 |
dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous SSc; BMI: body mass index; RP: Raynaud phenomenon; mRSS: modified Rodnan skin score; GERD: gastroesophageal reflux disease; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PAP: pulmonary arterial pressure; ANA: antinuclear antibody; ACA: anticentromere antibody; ARA: anti-RNA polymerase III.